Mr. Jonathan  Olefson

Gen. Counsel & Corporation Sec.

Mr. Jonathan  Olefson Esq.

Gen. Counsel, Corporation Sec. & Interim Chief HR Officer

Mr. Alistair  Macdonald

Advisor

Mr. Michael Lee Brooks

Chief Operating Officer

Ms. Michelle  Keefe

Chief Executive Officer & Director

Mr. Larry A. Pickett Jr.

Chief Information & Digital Officer

Mr. Jason M. Meggs

Chief Financial Officer

Mr. Baba  Shetty

Pres of Technology & Data Solutions

Ronnie  Speight

Senior Vice President of Investor Relations

Ms. Donna Hildebrand Kralowetz

Senior Vice President of Fin. & Chief Accounting Officer

Dr. Judith  Ng-Cashin M.D.

Chief Scientific Officer

Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health, clinical trial diversity, biometric, and regulatory affair services. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication services; and consulting services to the pharmaceutical, biotechnology, and healthcare industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.

Higher reimbursable expenses and growth in Deployment Solutions contribute to Commercial Solutions revenue growth at Syneos Health (SYNH).

Syneos Health (SYNH) Q4 Earnings Beat Estimates, Margins Down

Syneos Health, Inc. (NASDAQ:SYNH ) Q4 2022 Earnings Conference Call February 16, 2023 8:00 AM ET Company Participants Ronnie Speight - Senior Vice President, Investor Relations Michelle Keefe - Chief Executive Officer Jason Meggs - Chief Financial Officer Michael Brooks - Chief Operating Officer Conference Call Participants Patrick Donnelly - Citi David Windley - Jefferies Eric Coldwell - Baird Justin Bowers - Deutsche Bank Sandy Draper - Guggenheim Max Smock - William Blair Casey Woodring - JPMorgan Luke Sergott - Barclays Elizabeth Anderson - Evercore Operator Good morning, ladies and gentlemen. Welcome to the Syneos Health Fourth Quarter and Full Year 2022 Earnings Conference Call.

Syneos Health, Inc. (SYNH) Q4 2022 Earnings Call Transcript

Syneos Health (SYNH) delivered earnings and revenue surprises of 4.24% and 5.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Tops Q4 Earnings and Revenue Estimates

MORRISVILLE, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its fourth quarter and full year 2022 financial results on Thursday, February 16, 2023, prior to its earnings call at 8:00 a.m. ET.

Syneos Health Schedules Fourth Quarter and Full Year 2022 Earnings Call for Thursday, February 16th, 2023

Syneos Health (SYNH) inks a partnership with Cryoport to deliver seamless integration and insights for key services for cell and gene trial operations to biopharmaceutical customers.

Syneos Health (SYNH) Signs New Partnership With Cryoport

Powered by AI

Syneos Health, Inc.

41.65